Population Pharmacokinetics of Telmisartan in Healthy Subjects and Hypertensive Patients.

Background And Objective: Telmisartan exhibits significant pharmacokinetic (PK) variability, but it remains unclear whether its PK profile is altered in hypertensive patients. This study aimed to characterize telmisartan PKs by conducting a meta-analysis and developing a pooled population PK model based on data from healthy subjects and hypertensive patients.

Methods: Relevant literature was identified by a systematic approach.

External Validation of Two 10-Year Stroke Risk Prediction Models Using Korean Genome and Epidemiology Study Data.

This study aimed to externally validate two 10-year stroke risk prediction models: one developed in Korea (Model 1) and the other in China (Model 2), using community-based cohort data. Data from 8432 participants in Model 1 and 8915 participants in Model 2 were analyzed. Stroke risk was calculated based on each model's equations, and model performance was assessed using the area under the receiver operating characteristic curve (AUC).

Motile cilia modulate neuronal and astroglial activity in the zebrafish larval brain.

The brain uses a specialized system to transport cerebrospinal fluid (CSF), consisting of interconnected ventricles lined by motile ciliated ependymal cells. These cells act jointly with CSF secretion and cardiac pressure gradients to regulate CSF dynamics. To date, the link between cilia-mediated CSF flow and brain function is poorly understood.

Earth to Ashes: Cultural Transformations in the Cremation Rites of Modern and Contemporary South Korea.

Under Japanese rule in 1912, cremation was legalized in Korea, marking a shift from a strictly prohibited practice to an accepted funeral option. Initially viewed as a Japanese custom, cremation gradually transformed into a "civilized" choice, a perspective pushed by Japanese colonial authorities and some Korean modernizers. However, this narrative overlooks the gradual acceptance of cremation among Koreans.

Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP).

Background: The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor enavogliflozin effectively lowers glycosylated hemoglobin levels and body weights without the increased risk of serious adverse events; however, the long-term clinical benefits of enavogliflozin in terms of cardiovascular and renal outcomes have not been investigated.

Methods: This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults (aged ≥19 years) with type 2 diabetes mellitus (T2DM) who have a history of, or are at risk of, cardiovascular disease.